Abstract: Chemical compounds for the treatment of myeloid neoplasms and solid tumors are described, where the compounds were identified through a screening process assessing the binding affinity of the compounds to a synthesized fragment of Setbp1 protein.

Abstract: Compositions useful as poliovirus immunogens are provided along with methods and compositions for preparing the same. Compositions comprising poliovirus immunogens can enable a host response that includes virus-neutralizing antibodies which can protect the host from infection and/or disease.

Abstract: Antibodies and compositions of matter useful for the detection, diagnosis and treatment of Epstein Barr Virus (EBV) infection in mammals, and methods of using those compositions of matter for the detection, diagnosis and treatment of EBV infection are described. Also described are proteins, referred to as anti-gp350 antibody probes, and anti-gp350 B-cell probes, that maintain the epitope structure of the CR2-binding region of gp350, but do not bind CR2.

Abstract: Methods and kits to assess an absorbed dose of ionizing radiation and/or the severity of tissue injury from radiation in a patient. Also, algorithms used to calculate an absorbed dose of radiation based on biomarker measurements of a plurality of biomarkers that are altered relative to a normal control in the event of radiation exposure.

Abstract: Inhibitors against SARS-COV-1, SARS-CoV-2 (Covid-19), MERS-CoV, and variants within each, including methods of treating a subject suffering from such respiratory disease.

Abstract: Antibodies and compositions of matter useful for the detection, diagnosis and treatment of Epstein Barr Virus (EBV) infection in mammals, and methods of using those compositions of matter for the detection, diagnosis and treatment of EBV infection are described. Also described are proteins, referred to as anti-gp350 antibody probes, and anti-gp350 B-cell probes, that maintain the epitope structure of the CR2-binding region of gp350, but do not bind CR2.

Abstract: The present disclosure provides gene expression profiles that are associated with prostate cancer, including certain gene expression profiles that differentiate between subjects of African and Caucasian descent and other gene expression profiles that are common to subjects of both African and Caucasian descent. The gene expression profiles can be measured at the nucleic acid or protein level and used to stratify prostate cancer based on ethnicity. The gene expression profiles can also be used to identify a subject for prostate cancer treatment. Also provided are kits for diagnosing and prognosing prostate cancer and an array comprising probes for detecting the unique gene expression profiles associated with prostate cancer in subjects of African and/or Caucasian descent.

Abstract: The invention described herein provides antibodies to Zika virus. The novel polypeptides are useful alone or as portions of larger molecules, such as antibodies or antibody fragments, that can be used to treat or prevent infection of Zika virus.

Abstract: Antiviral drugs targeting the N-terminal domain (NTD) of the spike receptor binding domain (RBD) and methods of treating a subject suffering from coronavirus.

Abstract: Featured are methods, apparatus and devices for detecting a hematoma in tissue of a patient. In one aspect, such a method includes emitting near infrared light continuously into the tissue from a non-stationary near infrared light emitter and continuously monitoring the tissue using a non-stationary probe so as to continuously detect reflected light. The near infrared light is emitted at two distances from a brain of the patient, so the emitted light penetrates to two different depths. Such a method also includes applying a ratiometric analysis to the reflected light to distinguish a border between normal tissue and tissue exhibiting blood accumulation.

Abstract: The present disclosure relates to the field of vaccines and binding molecules, as well as preparations and methods of their use in the treatment and/or prevention of disease. Described are vaccines and binding molecules, compositions containing the same, and uses thereof for treating or preventing coronavirus infections, in particular, ?-coronaviruses such as SARS- CoV-2, the causative agent of COVID-19, as well as SARS-CoV-1 and other coronaviruses.

Abstract: In aspects, the disclosure provides a method of differentiating a malignant tumor from a non-malignant tumor in a mammal having a tumor comprising determining in a sample from the mammal the level of one or more of: (1) transthyretin (TTR) RNA or protein, (2) dual oxidase 2 (DUOX2) RNA or protein, and (3) G-protein coupled receptor 179 (GPR179) RNA or protein.

Abstract: Described are methods of treating or reducing the toxic effects of exposure to a nerve agent, comprising administering to a subject in need thereof (i) an AMPA/GluR5(GluK1) kainate receptor antagonist (such as LY293558) and (ii) an NMD A receptor antagonist (such as an antimuscarinic compound, such as caramiphen), as well as methods of treating, reducing the risks of, or preventing a neurological condition such as epilepsy, seizures, post-traumatic stress disorder, status epilepticus, depression, or anxiety, comprising administering to a subject in need thereof (i) an AMPA/GluR5(GluK1) kainate receptor antagonist (such as LY293558) and (ii) an NMDA receptor antagonist (such as an antimuscarinic compound, such as caramiphen). The methods may further comprise administering a positive allosteric modulator of synaptic GABAA receptors, such as a benzodiazepine, such as midazolam, to the subject. The methods are suitable for use in children and adults. Related compositions and uses also are described.

Abstract: Diffusion sensitizing gradient pulse pairs are prescribed in a manner to mitigate effects of concomitant gradient artifacts. Measured MR signals generated by applying a plurality of diffusion sensitizing gradient matrices are obtained and processed to determine a second order mean diffusion tensor and a fourth order covariance tensor. Quantities derived from these tensors are measured and mapped within an imaging volume which describe features of diffusion anisotropy and heterogeneity within each imaging voxel.

Abstract: Methods are disclosed for inducing an immune response to Neisseria gonorrhoeae in a mammalian subject. These methods include administering to the mammalian subject an effective amount of a MetQ protein and an effective amount of a K-type CpG oligodeoxynucleotide, thereby inducing the immune response. Also disclosed are immunogenic compositions including an effective amount of a MetQ protein and an effective amount of a K-type CpG oligodeoxynucleotide.

Abstract: Selective azophenol inhibitors of a wild type or an altered ERG protein expression are described, where the inhibitors represent a compound of Formula (I) or Formula (II) wherein X, X1, X2, X3, X4 and X5, R1 through R4 and R9 are as described.

Abstract: The present invention relates to methods and kits to assess an absorbed dose of ionizing radiation and/or the severity of tissue injury from radiation in a patient. The invention also relates to algorithms used to calculate an absorbed dose of radiation based on biomarker measurements of a plurality of biomarkers that are altered relative to a normal control in the event of radiation exposure.

Abstract: The invention relates to pharmaceutical compositions comprising at least one antigen and an adjuvant composition, where the adjuvant composition comprises a saponin and a liposome. The liposome of the composition comprises monophosphoryl lipid A (MPLA), cholesterol and a phospholipid that is in a liquid crystalline state at greater than or equal to 23° C., and the concentration of cholesterol to lipid in the liposome is greater than 50% (mol/mol). The antigen in the composition is a soluble Plasmodium falciparum recombinant circumsporozoite protein (rCSP) comprising the amino acid sequence of SEQ ID NO:1, or a P. falciparum rCSP peptide that is at least 95% identical to the amino acid sequence of SEQ ID NO:1.

Abstract: Provided are antigenic compositions and uses thereof that include at least two human herpesvirus (HHV) polypeptides involved in mediating HHV binding, fusion, and entry into host cells, such as gp350, gH, gL, and gB, or nucleic acids encoding the polypeptides. The two HHV polypeptides comprise any combination of: a gB polypeptide; a gp350 polypeptide; a gL polypeptide; and a gH polypeptide, and optionally any one or more of the following polypeptides: gp42, gM, gN, gl, gC, gE, gD, ORF68, BMRF-2, BDLF2, UL128, UL130, UL131A, and gpK8.1. Also disclosed are methods of inducing an immune response or treating or preventing an HHV infection in a subject by administering to the subject at least two of the HHV polypeptides or nucleic acid(s) encoding the same. Methods of passively transferring immunity using high-titer anti-HHV antibodies or immune cells are also disclosed.

Abstract: The present system is directed in several embodiments to a method of administration of a therapeutic composition for protection of the brain of a subject at risk of injury leading to traumatic brain injury (TBI) and/or treatment of injury to the brain resulting from TBI. The method includes administering one or more therapeutic compositions comprising an effective amount of insulin directly to the subject patient's CNS, with no to minimal systemic exposure. Preferably, this method comprises administration of an effective amount of insulin to the upper third of a patient's nasal cavity, thereby bypassing the patient's blood-brain barrier and delivering the therapeutic composition directly to the patient's central nervous system.